Monday 25 August 2014

High concordance between EGFR mutations from ctDNA and tumour tissue in NSCLC: ctDNA as a surrogate for determination of EGFR status

Epidermal growth factor receptor (EGFR) mutations found in the circulating-free tumour DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumour tissue DNA.
EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumour tissue, which can be limited or not available. A more abundant and less invasive source of tumour DNA may be cell free tumour DNA found circulating in the blood. Read more here

No comments:

Post a Comment